Article
A rationally designed A34R mutant oncolytic poxvirus: improved efficacy in peritoneal carcinomatosis.
Molecular therapy : the journal of the American Society of Gene Therapy - 1 May 2013
Thirunavukarasu Pragatheeshwar, Sathaiah Magesh, Gorry Michael C, O'Malley Mark E, Ravindranathan Roshni, Austin Frances, Thorne Steven H, Guo Zong Sheng, Bartlett David L
Abstract excerpt
Oncolytic poxviruses have demonstrated initial promising results in patients with cancer in clinical trials, yet further improvements are needed. It has been shown that a single point mutation in the A34R gene resulted in the production of more total progeny virus and more extracellular enveloped virus (EEV), a form that can be immune-evasive and with enhanced spread. We have genetically engineered a new...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.